InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,214.80
(
0.00%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.35
(
-0.15%
)
Bitcoin
60,663.50
(
-0.25%
)
Post# of 252389
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 126244

Wednesday, 09/07/2011 10:40:03 AM

Wednesday, September 07, 2011 10:40:03 AM

Post# of 252389
HSP’s Epogen project has modest commercial upside at best, IMO. The US market for Epogen biosimilars will probably end up looking like the one in Europe, where there are many branded products each generating a tiny market share.

I don’t think HSP will be a player at all in substitutable biogenerics.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up